Search Results

Business

TargImmune Announces Successful Completion of GLP/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development

TargImmune Therapeutics AG announced two major milestones - the appointment of Dr Marc Thommen as Head of Technical Development, and the successful completion of GLP/Tox studies.

June 7, 2022

·

3 min read

Business

TargImmune Announces Another Senior Hire as Veronica Hersberger Revealed As New Chief Medical Officer

TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients by developing novel targeted anticancer treatments, announced the further expansion of their management team with the appointment of Veronica Hersberger as Chief Medical Officer.

February 7, 2022

·

4 min read

Business

Race Joint Venture With TargImmune

July 10, 2017

·

4 min read

Deals

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber’s Hereditary Optic Neuropathy (LHON)

NAYA Biosciences Inc. today announced that it has entered into a binding letter of intent to acquire Florida Biotechnologies, Inc. a gene therapy company focusing on the treatment of mitochondrial diseases.

January 23, 2024

·

12 min read

Deals

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

INVO Bioscience, Inc. and NAYA Biosciences Inc. jointly announced that following the closing of their pending merger, Dr. Peter Kash, Ed.D., MBA will join the combined company’s Board of Directors as Vice Chairman.

November 10, 2023

·

11 min read

Pharm Country

Key Genetic Code Change Drives Common Lung Cancer Type

A team led by researchers at NYU Langone Health’s Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might be treated.

January 9, 2023

·

4 min read

Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

The rapid development of an effective and safe vaccine against SARS-CoV-2 is a top priority for Swiss Rockets AG

November 10, 2020

·

6 min read